Transition of Care of Disorders of Sexual Development: A Twist of Two Cases with Ambiguous Genitalia
DOI:
https://doi.org/10.66266/inajemd.v1i1.3Keywords:
Disorders of sexual development (dsd) , ambiguous genitalia , case seriesAbstract
Disorders of sexual development (DSD) is a congenital condition that requires an alteration in the development of chromosomal, gonadal, and anatomical sex is atypical. A report showed most of the patients in the 46XX DSD had congenital adrenal hyperplasia (CAH) at 69.23% followed by unknown under-virilization in the 46XY DSD group at 60.09%. Patient 1 diagnosed as DSD 46XX/non-classic congenital adrenal hyperplasia (NCAH) presented with primary amenorrhea, short stature, over-virilization (Prader 2), and 46XX karyotype. Laboratory examination showed elevated 17-hydroxyprogesterone (17OHP): 166.7 ng/ml (2.83 ng/ml), without salt wasting feature. Patient 2 diagnosed with DSD 46XY/type 2 5α -reductase deficiency (SAD) presented with cryptorchidism, under-masculinization (sinecker stage 3b), and 46XY karyotype. Laboratory examination showed elevated testosterone 613 ng/dL (4.6-38.3 ng/dL), decreased dihydrotestosterone (DHT) 11 ng/dL (>20 ng/dL), and elevated testosterone T/DHT ratio 55.73 (8-16). A deep understanding of pathophysiology, and approach to disease in each stage of life is important and warrants special treatment. Comprehensive multidisciplinary team management (MDT) is warranted in DSD management. Disease prognosis varies among each disorder: early detection, treatment compliance, and continuity of care are important to improve patient outcomes.
Downloads
References
1. Guerrero-Fernández J, Azcona San Julián C, Barreiro Conde J, Bermúdez de la Vega JA, Carcavilla Urquí A, Castaño González LA, et al. Guía de actuación en las anomalías de la diferenciación sexual (ADS)/ desarrollo sexual diferente (DSD). An Pediatría. 2018;89(5):315.e1-315.e19.
2. Lee PA, Houk CP, Ahmed SF, Hughes IA. Consensus statement on management of intersex disorders. International Consensus Conference on Intersex. Pediatrics. 2006 Aug;118(2):e488-500.
3. Granada ML, Audí L. The laboratory in the multidisciplinary diagnosis of differences or disorders of sex development (DSD). Physiol Classif approach. 2021;2(4):468–80.
4. Lee PA, Nordenström A, Houk CP, Ahmed SF, Auchus R, Baratz A, et al. Global disorders of sex development update since 2006: perceptions, approach, and care. Horm Res Paediatr. 2016;85(3):158-
80.
5. Walia R, Singla M, Vaiphei K, Kumar S, Bhansali A. Disorders of sex development: a study of 194 cases. Endocr Connect. 2018;7(2):364–71.
6. Listyasari NA, Santosa A, Juniarto AZ, Faradz SMH. Multidisciplinary management of disorders of sex development in indonesia, a prototype in developing country. J Biomed Transl Res. 2017;3(1):17–22.
7. Batista RL, Mendonca BB. Integrative and analytical review of the 5-alpha-reductase type 2 deficiency worldwide. Appl Clin Genet. 2020;13:83–96.
8. Avendaño A, Paradisi I, Cammarata-Scalisi F, Callea M. 5-α-reductase type 2 deficiency: is there a genotype-phenotype correlation? a review. Hormones. 2018;17(2):197–204.
9. Witchel SF, Azziz R. Nonclassic congenital adrenal hyperplasia. Int J Pediatr Endocrinol. 2010;2010:625105.
10. Carmina E, Dewailly D, Escobar-Morreale HF, Kelestimur F, Moran C, Oberfield S, et al. Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women. hum reprod update. 2017 Sep 1;23(5):580–99.
11. Berra M, Creighton SM, Rumbsby G, Honour J, Conway GS. 5 alpha reductase deficiency: redefining the diagnostic process in the adult setting. In 2010. p. P1-323.
12. Ng KL, Ahmed SF, Hughes IA. Pituitary-gonadal axis in male undermasculinisation. Arch Dis Child. 2000 Jan;82(1):54–8.
13. Lucas-Herald AK, Scougall K, Ahmed SF. Delivery of multidisciplinary care in the field of differences and disorders of sex development (DSD). Expert Rev Endocrinol Metab. 2022 May 4;17(3):225–34.
14. Adriaansen BPH, Schröder MAM, Span PN, Sweep FCGJ, van Herwaarden AE, Claahsen-van der Grinten HL. Challenges in treatment of patients with non-classic congenital adrenal hyperplasia. Front Endocrinol (Lausanne). 2022;13:1064024.
15. Speiser PW, Arlt W, Auchus RJ, Baskin LS, Conway GS, Merke DP, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2018 Nov 1;103 (11): 4043–88.
16. Han TS, Walker BR, Arlt W, Ross RJ. Treatment and health outcomes in adults with congenital adrenal hyperplasia. Nat Rev Endocrinol. 2014;10(2):115–24.
17. El-Maouche D, Arlt W, Merke DP. Congenital adrenal hyperplasia. Lancet.
2017 Nov; 390(10108):2194–210.
18. De Leo V, Morgante G, Piomboni P, Musacchio MC, Petraglia F, Cianci A. Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndrome. Fertil Steril. 2007 Jul 1;88(1):113–11.
19. Spritzer P, Billaud L, Thalabard JC, Birman P, Mowszowicz I, Raux-Demay MC, et al. Cyproterone acetate versus hydrocortisone treatment in late-onset adrenal hyperplasia. J Clin Endocrinol Metab. 1990 Mar;70(3):642–6.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 InaJEMD - Indonesian Journal of Endocrinology Metabolic and Diabetes
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain copyright and grant the Indonesian Journal of Endocrinology, Metabolism and Diabetes (InaJEMD) the right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
© Indonesian Journal of Endocrinology, Metabolism and Diabetes (InaJEMD). Published by the Indonesian Society of Endocrinology (PERKENI).
